Problems assessment for substance using psychiatric patients: development and initial psychometric evaluation
Problems assessment for substance using psychiatric patients: development and initial psychometric evaluation
复制标题
DOI：
10.1016/j.drugalcdep.2004.01.010
复制
发表时间：
2004-07-15
影响因子：
4.2
通讯作者：
Neal, DJ
中科院分区：
文献类型：
--
作者：
Carey, KB;Roberts, LJ;Neal, DJ
工作背景：患有共同发生的轴I精神障碍和物质使用障碍的人经常因其物质使用而经历多种负面后果。由于没有现有的措施充分评估这些特定人群的问题，我们开发了物质使用精神病患者的问题评估（PASUPP）。本文介绍了PASUPP的量表编制和因素结构，并为PASUPP提供了初步的信度和效度证据。方法：通过回顾相关项目的现有措施并生成新项目，初步汇集了54个项目。然后，239例（90%男性，61%白色）记录轴I精神和目前的物质使用障碍的生活和最后3个月发生的每一个问题，并完成了额外的措施，物质使用和相关功能。结果：终身认可的范围从31%到95%，而3个月的认可范围从24%到78%。项目分析减少了50个项目。PASUPP内部一致（α = 0.97）且为一维。量表的有效性建议与物质问题严重程度的其他措施的中度相关。结论：有前途的心理测量性能报告的物质使用问题的人群特异性措施。这样的措施可能是有用的初步评估和结果评价与物质使用精神病患者。(C)2004爱思唯尔爱尔兰有限公司保留所有权利。
Background: Persons with co-occurring Axis I mental disorders and substance use disorders often experience multiple negative consequences as a result of their substance use. Because no existing measure adequately assesses these population-specific problems, we developed the Problems Assessment for Substance Using Psychiatric Patients (PASUPP). This paper describes the scale development and factor structure, and provides initial reliability and validity evidence for the PASUPP. Methods: An initial pool of 54 items was assembled by reviewing existing measures for relevant items and generating new items. Then, 239 patients (90% male, 61% White) with documented Axis I psychiatric and current substance use disorders rated the lifetime and last 3-month occurrence of each problem, and completed additional measures of substance use and related functioning. Results: Lifetime endorsements ranged from 31 to 95%, whereas 3-month endorsements ranged from 24 to 78%. Item analyses reduced the set to 50 items. The PASUPP is internally consistent (alpha = 0.97) and unidimensional. Scale validity was suggested by moderate correlation with other measures of substance problem severity. Conclusions: Promising psychometric properties are reported for a population-specific measure of substance use problems. Such a measure could be useful for initial assessments and outcome evaluations with substance using psychiatric patients. (C) 2004 Elsevier Ireland Ltd. All rights reserved.